LCM
CTMX icon

Landscape Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Landscape Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Hold
94,240
– – 0.02% 532
2026
Q1 		$443K Buy
+94,240
New +$478K 0.03% 522
2017
Q2 		– Sell
-70,943
Closed -$1.23M – 344
2017
Q1 		$1.23M Buy
+70,943
New +$934K 0.12% 154

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Landscape Capital Management's CTMX Position: Q2 2026 in Review

Landscape Capital Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 94,240 shares worth $353K. The position accounts for 0.02% of the portfolio, ranked #532.

Landscape Capital Management first reported a position in CTMX in Q1 2017 and has held it in 3 quarters since. The position peaked at $1.23M in Q1 2017. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Landscape Capital Management held 94,240 shares of CytomX Therapeutics worth $353K as of Q2 2026.
  • Landscape Capital Management left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up 0.02% of Landscape Capital Management's portfolio in Q2 2026, its #532 holding.
  • Landscape Capital Management first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 3 quarters since.
  • Landscape Capital Management's CytomX Therapeutics position peaked at $1.23M in Q1 2017.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.